Michael Liss, MD, PhD, MAS, FACS Urology Oncology, Prostate Cancer
EA8171, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (CTMS# 18-0091)
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer, NRG-GU006 (CTMS# 18-0115)
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.
Yoga improves quality of life in men with new diagnosis of prostate cancer
Yoga improved physical and mental well-being and promoted a robust immune response in a randomized clinical trial of men with prostate cancer.
Clinical trial tackles the question of how much treatment is enough for prostate cancer
According to the National Cancer Institute, more than 3 million men are living with prostate cancer in the United States. Of those, survivorship after five years is 97 percent. With patients living longer and physicians seeing younger patients with this type of cancer, learning the best ways to treat patients and providing a better […]
Mays Cancer Center’s latest radiation therapy reduces treatment times, increases favorable outcomes for prostate cancer
Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, introduces the newest technology in treating prostate cancer. This innovative method is called stereotactic body radiation therapy (SBRT), a minimally invasive therapy using high amounts of radiation with millimeter precision to destroy tumors in the prostate. Stereotactic body radiation therapy is a […]
UT Health San Antonio study shows MRI technique improves detection of aggressive prostate cancer
An MRI scan called restriction spectrum imaging greatly improves the detection of prostate cancer progression, according to a published study by researchers at The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio.